The sole vaccine currently available is more than a century old, plus it does not adequately protect young people and adults, who account for most TB transmissions.“We need to make the tools we have available to more people. But we also need new tools,” said WHO chief Tedros Adhanom Ghebreyesus, speaking in Geneva. “Increasing drug resistance is undermining the effectiveness of some medicines that are used to treat TB,” he added.
Equitable access to services
The flagship initiative aims to spur action and accountability to tackle the key drivers of the TB epidemic, such as poverty, undernourishment, diabetes, HIV, tobacco and alcohol use, and poor living and working conditions. TB mainly affects the lungs, but it is preventable, treatable and curable. Although deaths have dropped by nearly 40 per cent globally since the year 2000, 1.6 million people die from the disease annually, and millions more are affected.
New tools needed
On the eve of World Tuberculosis Day, WHO announced that it will expand the scope of a five-year-old initiative in efforts to eradicate one of the world’s top infectious killers by 2030. WHO also highlighted the pressing need for investment, particularly in new vaccine development, and has proposed the establishment of a TB Vaccine Acceleration Council. The WHO Director-General’s Flagship Initiative on TB was established in 2018 to advance research and increase access to services, in support of efforts to end the global epidemic. It will now be expanded and extended through 2027.
Call to action
The UN General Assembly will convene a High-Level Meeting on TB in September, which Tedros said “should be a turning point in the fight against TB, if leaders make real and lasting commitments to invest in the response to TB.” WHO and partners have also issued a call to action for governments to accelerate the rollout of new oral treatment regimens for drug-resistant TB, which continues to be a pressing health concern. The aim is to scale up delivery of quality care to people living with TB through equitable access to rapid diagnostics and shorter all-oral treatment.